Literature DB >> 839852

Antibiotic prophylaxis for open-heart surgery.

P D Myerowitz, K Caswell, W G Lindsay, D M Nicoloff.   

Abstract

A randomized, prospective study of the relative effectiveness of broad-spectrum versus specific antistaphylococal antibiotic prophylaxis in patients having open-heart surgery was performed between May, 1972, and June, 1973. All patients undergoing open-heart surgery was assigned randomly (by hospital number) to receive either methicillin or cephalothin beginning the night before operation. There were 132 patients in the cephalothin group and 129 in the methicillin group. There was no statistically significant differences in age or duration of hospitalization, cardiopulmonary bypass, urinary tract drainage, or postoperative fever. There was a significant difference in the ratio of male to total patients (cephalothin group, 0.67; methicillin group, 0.52; p less than 0.02) and duration of operation (cephalothin group, 4.27 hours; methicillin group, 3.87 hours; p less than 0.05). The methicillin group had a statistically significant higher rate of urinary tract infection (cephalothin group, 3 cases; emthicillin group, 22 cases, p less than 0.05), pneumonia (cephalothin group, no cases; methicillin group, 9 cases; p less than 0.01), and episodes of sepsis and prosthetic valve endocarditis (cephalothin group, no cases; methicillin group, 11 cases, p less than 0.001). The incidence of wound infections and positive blood cultures from blood obtained immediately after termination of cardiopulmonary bypass was not significantly different between the two groups. Cephalothin has replaced methicillin as the routine prophylaxis for open-heart surgery at our institution.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 839852

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  12 in total

1.  Perioperative antibiotic prophylaxis in cardiovascular surgery: a prospective randomized comparative trial of cefazolin versus ceftriaxone.

Authors:  M Soteriou; F Recker; S Geroulanos; M Turina
Journal:  World J Surg       Date:  1989 Nov-Dec       Impact factor: 3.352

2.  In vitro activity of six antibiotics against multiresistant staphylococci and other gram-positive cocci.

Authors:  S Dixson; W Brumfitt; J M Hamilton-Miller
Journal:  Eur J Clin Microbiol       Date:  1985-02       Impact factor: 3.267

3.  Antibiotic prophylaxis in cardiothoracic surgery in the United Kingdom: current practice.

Authors:  A P Wilson; T Treasure; M F Sturridge; R N Grüneberg
Journal:  Thorax       Date:  1986-05       Impact factor: 9.139

Review 4.  Cephalosporins in surgery. Prophylaxis and therapy.

Authors:  D W McEniry; S L Gorbach
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Randomized comparison of cefamandole, cefazolin, and cefuroxime prophylaxis in open-heart surgery.

Authors:  T G Slama; S J Sklar; J Misinski; S W Fess
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

6.  Comparison of cephalothin and cefamandole prophylaxis during insertion of prosthetic heart valves.

Authors:  G L Archer; R E Polk; R J Duma; R Lower
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

7.  Plasma and myocardial levels of cefonicid during open-heart surgery.

Authors:  R P Sterling; D J Connor; J C Norman
Journal:  J Natl Med Assoc       Date:  1983-11       Impact factor: 1.798

8.  Ceftizoxime level in the myocardium (right atrial muscle and mitral papillary muscle) during open heart surgery.

Authors:  M Kobayashi; M Washio; H Eishin; T Shimanuki; H Orita; T Sato
Journal:  Jpn J Surg       Date:  1988-03

9.  Bacteremia following prosthetic valve replacement.

Authors:  F B Parker; C Greiner-Hayes; R H Tomar; A H Markowitz; E L Bove; M A Marvasti
Journal:  Ann Surg       Date:  1983-02       Impact factor: 12.969

10.  The microbiological risk of invasive hemodynamic monitoring in adults undergoing cardiac valve replacement.

Authors:  J Damen
Journal:  J Clin Monit       Date:  1986-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.